Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.